Clinical Trial Update: Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of ABI-007 administered weekly in chemotherapy-naive patients with advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ABI-007 (nab-paclitaxel)

Snippet

Sponsor: Celgene Corporation | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED